Australia markets closed

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (603896.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
27.92-0.26 (-0.92%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 5.69B
Enterprise value 4.97B
Trailing P/E 19.17
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.39
Price/book (mrq)2.76
Enterprise value/revenue 5.75
Enterprise value/EBITDA 15.58

Trading information

Stock price history

Beta (5Y monthly) 0.37
52-week change 3-43.00%
S&P500 52-week change 325.97%
52-week high 358.66
52-week low 323.07
50-day moving average 329.56
200-day moving average 337.76

Share statistics

Avg vol (3-month) 31.96M
Avg vol (10-day) 32.73M
Shares outstanding 5201.83M
Implied shares outstanding 6201.83M
Float 8112.91M
% held by insiders 143.18%
% held by institutions 121.33%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.44
Forward annual dividend yield 41.58%
Trailing annual dividend rate 30.44
Trailing annual dividend yield 31.56%
5-year average dividend yield 40.89
Payout ratio 429.93%
Dividend date 3N/A
Ex-dividend date 404 July 2023
Last split factor 21.3:1
Last split date 326 May 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 33.22%
Operating margin (ttm)21.07%

Management effectiveness

Return on assets (ttm)5.44%
Return on equity (ttm)15.31%

Income statement

Revenue (ttm)864.06M
Revenue per share (ttm)4.41
Quarterly revenue growth (yoy)8.20%
Gross profit (ttm)N/A
EBITDA 284.28M
Net income avi to common (ttm)287.01M
Diluted EPS (ttm)1.47
Quarterly earnings growth (yoy)2.10%

Balance sheet

Total cash (mrq)1.42B
Total cash per share (mrq)7.16
Total debt (mrq)701.74M
Total debt/equity (mrq)34.09%
Current ratio (mrq)3.41
Book value per share (mrq)10.38

Cash flow statement

Operating cash flow (ttm)316.33M
Levered free cash flow (ttm)-237M